Mitomycin

Description

Mitomycin · CAS 50-07-7 · C15H18N4O5. UNII 50SG953SK6. Boiling Point: 534; Melting Point: Above 680 °F (EPA, 1998); Melting Point: >360 °C.

Identification

CAS Registry Number	50-07-7
PubChem CID	5746
Molecular formula	C15H18N4O5
IUPAC name	[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
UNII (FDA)	50SG953SK6

Computed Descriptors

Molecular Weight	334.33
XLogP3	-0.4
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	4
Exact Mass	334.12771969
Monoisotopic Mass	334.12771969
Topological Polar Surface Area	147
Heavy Atom Count	24
Formal Charge	0

Physical & Chemical Properties

Boiling Point	534
Melting Point	Above 680 °F (EPA, 1998)
Melting Point	>360 °C
Melting Point	ABOVE 360 °C
Melting Point	> 360 °C
Solubility	Soluble (8430 mg/L)
Solubility	1.01e+01 g/L
LogP	-0.4
LogP	logP = -0.40
LogP	-1.6

Physical description & handling notes

• Mitomycin c appears as blue-violet crystals. Used as an anti-tumor antibiotic complex. (EPA, 1998)
• Water-soluble crystals that are blue-violet; [CAMEO]
• Solid
• BLUE-VIOLET CRYSTALS
• Soluble (NTP, 1992)
• SOL IN WATER, METHANOL, BUTYL ACETATE, ACETONE, AND CYCLOHEXANONE; SLIGHTLY SOL IN BENZENE, ETHER, AND CARBON TETRACHLORIDE; PRACTICALLY INSOL IN PETROLEUM ETHER.

GHS Hazard Classification

Reported hazard statements	H300 (75.4%), H301 (21.7%), H351 (94.2%)

Documented Uses

• Used as an alkylating agent in cancer chemotherapy; [HSDB]
• For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery.
• PRODUCED BY STREPTOMYCES CAESPITOSUS (GRISEOVINACESEUS).
• Yamamoto, Kenkyusho, Japan pat. 2898 (1956); Kenkyusho, Brit. pat. 830,874 (1960 to Kyowa); Gourevitch et al, U.S. pat. 3,042583 (1962 to Bristol-Myers) /production of the complex/
• Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-: ACTIVE
• For the treatment of malignant neoplasms of the lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also indicated as an adjunct to ab externo glaucoma surgery. Mitomycin is further indicated as a pyelocalyceal solution for adults with low-grade upper tract urothelial cancer (LG-UTUC) and for patients with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)

Synonyms

mitomycin C; Mitomycin; 50-07-7; Mutamycin; Ametycine; Mitomycin-C; Mitocin-C; Ametycin; Mitomycinum; Mytomycin; Mytozytrex; Mitomycinum C; Mitocin C; Mitamycin; Mitosol; NSC-26980

Frequently Asked Questions

What are the CAS number and molecular formula of Mitomycin?

CAS 50-07-7; molecular formula C15H18N4O5; molecular weight — g/mol.

What other names is Mitomycin known by?

mitomycin C, Mitomycin, 50-07-7, Mutamycin, Ametycine, Mitomycin-C.

Is Mitomycin classified as hazardous?

Hazard statements reported: H300, H301, H351.

What are the key physical properties of Mitomycin?

Boiling Point: 534; Melting Point: Above 680 °F (EPA, 1998); Melting Point: >360 °C; Melting Point: ABOVE 360 °C.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.